Study ID: GSK MHE104317

A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome


The purpose of this compassionate use supply program (CUSP) is to provide a treatment option to patients with life-threatening HES whose symptoms are not controlled with other therapies and to provide continued access to mepolizumab for subjects who received clinical benefit in another study, MHE100901, following termination of the study. Participants in this study have been asked by their physician to consider receiving an investigational drug called mepolizumab for treatment of their Hypereosinophilic Syndrome (HES). Eosinophils are a type of white blood cell that help fight certain types of infections. An elevated level of eosinophils in the blood is called hypereosinophilia. Prolonged hypereosinophilia may lead to physical symptoms caused by damage to different organs, such as in the lung. The combination of prolonged hypereosinophilia and eosinophil-related disease in at least one organ is called Hypereosinophilic Syndrome (HES).

Fargo Region
Principal Investigator:
Louis Geeraerts, MD
HEME (Hemetologic)


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list